Dr. Papaemmanuil is an Assistant Attending Computational Oncologist. She is affiliated with the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and is the Associate Director for the Center of Hematological Malignancies. Dr. Papaemmanuil was trained in Human Molecular Genetics at the University of Glasgow, completed PhD studies in Population Genetics and Epidemiology, and conducted her postdoctoral research at the Cancer Genome Project at the Wellcome Trust Sanger Institute in Cambridge UK. Dr. Papaemmanuil is a certified computer systems and operations development analyst by the British Society of Computing. Dr. Papaemmanuil’s research is focused on developing comprehensive laboratory and novel analytical methodologies to study the role of acquired mutations in cancer, and how these define clinical phenotype and determine therapeutic response. Dr. Papaemmanuil works with large and well-annotated clinical trial cohorts to study the diagnostic, prognostic and predictive value of genomic variation and how this knowledge can guide development of future clinical protocols. To this effect she is leading a number of international multi-center consortia including the prospective molecular characterization for the International Working Group in myelo-displastic syndromes, the pan-myeloid meta-analysis, and genome profiling of the UK acute lymphocytic leukemia clinical trials. At MSK, Dr. Papaemmanuil leads integrative whole genome, transcriptome and methylation studies of spatially and temporally separated samples in pediatric tumours. These studies are focused on understanding the genomic and clonal structure of pediatric genomes at diagnosis and how these change during therapy, and importantly, at disease progression. Informed by genomic findings, Dr. Papaemmanuil uses primary patient tissues to study the biological consequences of disease defining mutations in cancer using single cell and iPSC cell lies. Dr. Papaemmanuil is a European Society of Hematology Fellow, an American Society for Hematology Scholar, and a Josie Robertson Investigator.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Elli Papaemmanuil discloses the following relationships and financial interests:
TenSixteen Bio, Inc.
Ownership / Equity Interests; Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.